Saturday, December 28, 2024 12/28/2024

Secondary Prevention Following Acute Coronary Syndrome Using Integrated Smoking Cessation and Mood Management

Award Number: R01HL136327
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary/Abstract Approximately 400,000 smokers survive an Acute Coronary Syndrome (ACS; unstable angina, ST and non-ST elevation myocardial infarction) each year in the US. The occurrence of ACS can be conceptualized as a “teachable moment,” whereby patients may be more receptive to smoking cessation messages. Continued smoking following ACS is an independent predictor of mortality. Depressed mood post-ACS is also predictive of mortality, and smokers with depressed mood are less likely to abstain from smoking following an ACS hospitalization. Thus, a single, integrated treatment that targets both depressed mood and smoking could be highly effective in reducing post-ACS mortality. Behavioral Activation may be an ideal counseling treatment for this population because it is easy to train, can be delivered by Bachelor's degree level practitioners, and has recently shown promise for enhancing cessation outcomes in smokers with depression. Through extensive pilot work we systematically developed a counseling intervention that integrates gold standard smoking cessation counseling with Behavioral Activation based mood management for post-ACS smokers; Behavioral Activation Treatment for Cardiac Smokers (BAT-CS). The overall aim of the current study is to conduct a fully powered efficacy trial enrolling 324 smokers with ACS and randomizing them to 12 weeks of BAT-CS or control (including full attention match). Both groups will be offered the nicotine patch if medically cleared. Follow-up assessments will be conducted at end-of-treatment and 6, 9, and 12 months after hospital discharge. We will track the occurrence of major adverse cardiac events and all-cause mortality for 18-36 months post-discharge. The primary outcomes will be depressed mood and biochemically validated 7-day point prevalence abstinence. The specific aims of the study are: Aim I: Test the efficacy of BAT-CS vs. control on depressed mood and smoking cessation. Aim II: Test the efficacy of BAT-CS vs. control on cardiac health. Aim III: Explore hypothesized mediators of treatment effects. Aim IV: Explore the temporal interaction of smoking and multiple aspects of mood over 1 year post-ACS. The long-term goal of this line of research is to improve long-term survival rates following ACS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	000	5	6/25/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	000	5	6/2/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $573,592 )
2022	2022	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	001	5	6/29/2022	NON-COMPETING CONTINUATION	$57,361
2022	2022	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	000	5	4/1/2022	NON-COMPETING CONTINUATION	$516,231
														Subtotal = $573,592

Issue Date FY: 2021 ( Subtotal = $619,859 )
2021	2021	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	001	4	4/14/2021	NON-COMPETING CONTINUATION	$619,859
2021	2019	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	000	3	2/23/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $619,859

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	000	3	5/22/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $631,188 )
2019	2019	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	000	3	8/13/2019	NON-COMPETING CONTINUATION	$631,188
														Subtotal = $631,188

Issue Date FY: 2018 ( Subtotal = $623,032 )
2018	2018	MINNEAPOLIS MEDICAL RESEARCH FOUNDATION	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	000	2	7/16/2018	NON-COMPETING CONTINUATION	$623,032
														Subtotal = $623,032

Issue Date FY: 2017 ( Subtotal = $475,010 )
2017	2017	MINNEAPOLIS MEDICAL RESEARCH FOUNDATION	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Cardiovascular Diseases Research	000	1	8/16/2017	NEW	$475,010
														Subtotal = $475,010

Grand Total All Awards = $2,922,681

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Secondary Prevention Following Acute Coronary Syndrome Using Integrated Smoking Cessation and Mood Management

Award Number: R01HL136327

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer